Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-04 17:45 |
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of Decembe…
|
English | 175.3 KB | ||
| 2023-12-21 17:45 |
Informations privilégiées / Autres communiqués
|
French | 219.6 KB | ||
| 2023-12-21 17:45 |
Inside Information / Other news releases
|
English | 219.0 KB | ||
| 2023-12-05 17:45 |
Informations privilégiées / Autres communiqués
|
French | 359.5 KB | ||
| 2023-12-05 17:45 |
Inside Information / Other news releases
|
English | 358.9 KB | ||
| 2023-11-07 17:45 |
Information financière trimestrielle / Information financière du troisième trim…
|
French | 364.0 KB | ||
| 2023-11-07 17:45 |
Quarterly financial reporting / Third quarter financial report
|
English | 261.2 KB | ||
| 2023-10-10 07:30 |
Informations privilégiées / Autres communiqués
|
French | 273.1 KB | ||
| 2023-10-10 07:30 |
Inside Information / Other news releases
|
English | 209.0 KB | ||
| 2023-09-20 17:45 |
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise …
|
French | 168.1 KB | ||
| 2023-09-20 17:45 |
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | 1.9 MB | ||
| 2023-09-20 17:45 |
Half yearly financial reports and audit reports/limited reviews / Terms of avai…
|
English | 178.1 KB | ||
| 2023-09-20 17:45 |
Inside Information / News release on accounts, results
|
English | 376.4 KB | ||
| 2023-09-20 17:45 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 432.4 KB | ||
| 2023-09-20 17:45 |
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
|
French | 1.9 MB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
